{
 "name": "朗齊生醫",
 "slug": "tw-6876",
 "aliases": [
  "朗齊生物醫學股份有限公司",
  "LaunXP BioMed",
  "6876"
 ],
 "ticker": "6876",
 "industry": "生技醫療業",
 "website": "www.launxp.com",
 "summary": "朗齊生醫（6876）是興櫃的生技醫療類股公司，2015 年成立，2024 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "朗齊生物醫學股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "LaunXP BioMed",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2024-01-18",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2015-09-24",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "王繼賢",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "陳丘紘",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 1189416337,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "www.launxp.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：LXP103",
   "value": "代謝疾病／肥胖｜臨床前開發、準備IND申報｜地區未揭露",
   "unit": "",
   "as_of": "2026-03-18",
   "source": "https://launxp.com/wp-content/uploads/2026/03/0318%E6%9C%97%E9%BD%8A%E7%94%9F%E9%86%AB%E6%B3%95%E8%AA%AA%E6%9C%83%E7%B0%A1%E5%A0%B1.pdf",
   "note": "臨床前及IND準備進度依公司法說簡報；非已獲IND核准。"
  },
  {
   "claim": "管線：LXP1788",
   "value": "晚期實體腫瘤｜第I期已收治首位病患｜台灣",
   "unit": "",
   "as_of": "2025-02-17",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=161613&spoke_date=20250217&co_id=6876&TYPEK=rotc",
   "note": "發言日期：114/02/17；主旨：本公司研發小分子新藥LXP1788於台灣進行之實體腫瘤 (Solid tumor)人體一期臨床試驗已完成第一位病患 (First Patient In)之收治。。 試驗登錄：NCT06883539 https://clinicaltrials.gov/study/NCT06883539 。"
  },
  {
   "claim": "管線：LXP105",
   "value": "三陰性乳癌新輔助治療｜探索性臨床研究已完成、後續設計規劃中｜地區未揭露",
   "unit": "",
   "as_of": "2026-09-23",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=4&spoke_time=170813&spoke_date=20260923&co_id=6876&TYPEK=rotc",
   "note": "發言日期：115/09/23；主旨：(更正文字)公告LXP105應用於第二期三陰性乳癌(Triple- Negative Breast Cancer, TNBC）新輔助治療的探索性臨床研究， 獲國際腫瘤學期刊《Frontiers in Oncology》接受並準備發表。。原文為單中心探索性研究，非供查驗登記使用，不推定為註冊用Phase II成功。"
  },
  {
   "claim": "管線：LXP109",
   "value": "非小細胞肺癌｜臨床推動暫緩｜亞洲（不含中國大陸、香港及澳門）",
   "unit": "",
   "as_of": "2026-06-09",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=4&spoke_time=165537&spoke_date=20260609&co_id=6876&TYPEK=rotc",
   "note": "發言日期：115/06/09；主旨：公告本公司為提高資源配置效益，加速LXP103專案， 經董事會決議暫緩子公司LXP109臨床試驗案。授權區域補充來源：https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=162019&spoke_date=20250328&co_id=6876&TYPEK=rotc"
  },
  {
   "claim": "授權合作：LXP109（終止通知爭議中）",
   "value": "Apollomics Inc.｜亞洲（不含中國大陸、香港及澳門）｜2025-03-31",
   "unit": "",
   "as_of": "2026-10-15",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=160829&spoke_date=20261015&co_id=6876&TYPEK=rotc",
   "note": "發言日期：115/10/15；主旨：(更新進度)代子公司LAUNXP INTERNATIONAL CO., LTD. 公告接獲Apollomics Inc. 合作暨授權協議終止通知。子公司收到對方終止通知並持不同意見；仍協商補充文件，不能視為無爭議存續。區域依2025-03-28董事會公告：https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=162019&spoke_date=20250328&co_id=6876&TYPEK=rotc"
  },
  {
   "claim": "催化劑：LXP1788",
   "value": "第I期主要完成（試驗登錄預估）｜2027-12-31｜已公告",
   "unit": "",
   "as_of": "2025-03-19",
   "source": "https://clinicaltrials.gov/study/NCT06883539",
   "note": "NCT06883539；primaryCompletionDateStruct.type=ESTIMATED。整體試驗完成預估2028-06-30在18個月窗口外，未列。登錄最後更新2025-03-19，不代表實際已完成。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6876.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}